Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma. Biological Response Modifiers in Melanoma (BREMIM) Italian Cooperative Group.
In phase II, the tolerance and activity of dacarbazine and recombinant interferon alfa-2a (rIFN) was studied in 79 patients with metastatic melanoma. The regimen was well tolerated. Response rate was 25%, with 8% having a complete response. Response duration and survival after a follow-up of 39 months are reviewed. The mean durations of complete and partial responses are 13.7 months (range 1 to 31+) and 10 months (2 to 36+), respectively. Median time to progression is 3 months; median survival is 9 months. At present, 11% of treated patients are alive, thus addition of rIFN to dacarbazine may prolong response duration.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003606:Dacarbazine / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D011994:Recombinant Proteins; D013997:Time Factors
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003606:Dacarbazine